Coherus Oncology, Inc.
CHRS
$1.57
-$0.01-0.63%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.
3/14/2026
-
MarketBeat
3/14/2026
-
MarketBeat
3/9/2026
-
MarketBeat
3/9/2026
-
MarketBeat
3/9/2026
-
Globe Newswire
3/8/2026
-
SeekingAlpha.com: All News
3/8/2026
-
Seeking Alpha - Healthcare
3/2/2026
-
Globe Newswire
3/2/2026
-
MarketBeat
2/24/2026
-
MarketBeat
2/23/2026
-
Globe Newswire
2/17/2026
-
Globe Newswire
2/16/2026
-
MarketBeat
2/13/2026
-
Globe Newswire
2/12/2026
-
Globe Newswire
2/10/2026
-
MarketBeat
2/5/2026
-
TipRanks Financial Blog
2/4/2026
-
TipRanks Financial Blog
1/27/2026
-
PR Newswire
1/27/2026
-
CNW Group - News Releases
1/23/2026
-
TipRanks Financial Blog
1/23/2026
-
Stock Options Channel
1/23/2026
-
MarketBeat
1/23/2026
-
MarketBeat
1/17/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 9, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 649 3530
Address
333 Twin Dolphin Drive
Redwood City, CA 94065
Redwood City, CA 94065
Country
Year Founded
Business Description
Sector
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to...
more